US equities |
SPCX $167.06 ▲+5.10% NVDA $237.09 ▲+1.34% MU $1,063.54 ▼-1.06% TSLA $378.11 ▲+2.03% MSFT $527.20 ▲+1.87% SNDK $1,713.69 ▼-0.37% INTC $116.58 ▼-2.30% META $746.52 ▲+2.53%
FinancialContent

Articles published by TransCode Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Withdraws Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics CEO Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Closing of $7 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics to present at AACR Annual Meeting 2023
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
News headline image
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers RNAZ
< Previous 1 2 Next >